MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyApoptosis PharmacologyApoptosis ResistanceBcl-2 Family ProteinsChemotherapy ResistanceCytotoxic ChemotherapyTherapeutic ResistanceAnti-apoptotic AgentsAnti-apoptotic RegulatorsAnticancer Drug ResistanceAtaxia Telangiectasia And Rad3-related InhibitionChronic Lymphocytic Leukemia TherapyOvercoming Multidrug ResistancePro-apoptotic Bcl-2 ProteinsProtein Kinase Inhibitors
AIM: To perform the comparative study of the effects of DNA-dependent protein kinase (DNA-PK) inhibitors vanillin and NU7026, ataxia telangiectasia mutated kinase (ATM)/ ATM and Rad3 related (ATR) kinase inhibitor caffeine and multidrug resistance (MDR) protein modulator cyclosporine A (CsA) on fludarabine resistant and sensitive lymphocytes from chronic lymphocytic leukemia (CLL) patients. METHODS: Cells sensitivity in vitro was determined with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). DNA-PKs and ATM expression in CLL cells was evaluated using Western blotting. Multidrug tansporter protein expression and function was assessed by flow cytometry. Pro- or anti-apoptotic genes (BAX, LICE BCL-2, BCL-XS FLICE, FAS, TRAIL) expression on mRNA level was evaluated. RESULTS: Caffeine, vanillin, NU7026 and CsA increased fludarabine cytotoxicity against fludarabine-resistant CLL cells samples in comparison with sensitive cell samples. However, fludarabine-sensitive CLL samples were sensitized with inhibitors to a greater extent compared with resistant CLL samples. ATM expression increased in fludarabine-resistant CLL samples, but no apparent correlation between DNA-PKs level and fludarabine sensitivity in vitro or sensitization effect of DNA-PK inhibitors were observed. Fludarabine-resistant CLL lymphocytes showed tendency for depressed MDR efflux and decreased level of mRNA of pro-apoptotic gene BCL-XS. CONCLUSION: Absence of any definite conformity between fludarabine-resistant cell susceptibility to combined action of fludarabine and inhibitors, and molecular pathways that might be involved in this process does not exclude drugs synergy in fludarabine-resistant cells that could be used for overcoming resistance to nucleoside analogs in CLL.
17
Michael Hallek, Bruce D. Cheson, Daniel Catovsky et al. · Blood · 2008 · 3.2K citations · Full text
Medicine, Hematology, Oncology +14
Ian W. Flinn, Donna Neuberg, Michael R. Grever et al. · Journal of Clinical Oncology · 2007 · 402 citations · Full text
Medicine, Oncology, Pharmacotherapy +12
Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia
Míriam Molina‐Arcas, Beatríz Bellosillo, F. Javier Casado et al. · Blood · 2003 · 106 citations · Full text
Medicine, Oncology, Pharmacology +10